For all chronic illnesses, from rheumatoid arthritis to asthma to high blood pressure, patients usually relapse as soon as their treatment stops
Ben-Shlomo et al
[VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale By Katie Anderson, Chief Editor, Pharmaceutical Online After shifting to accommodate the GLP-1 growth in the past five years, the pharmaceutical industry must continue to strategize and innovate to accommodate the rapid growth that is still projected into 2030
However, for most conditions, results remained consistent across independent cohorts, with meta-analysis reinforcing the robustness of observed associations
These findings have led to NICE recommendations supporting the use of certain GLP-1 receptor agonists in patients with type 2 diabetes and established cardiovascular disease or at high cardiovascular risk
This dramatically increases side effect severity without meaningfully speeding up results